TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence In the interim analysis of the ...

For people facing aggressive bladder cancer that no longer responds to standard treatment, options have often been grim—either undergo life-changing surgery to remove the bladder or try less effective ...

The study is ongoing, and future analyses will include survival outcomes, researchers say. Adding TAR-200 to neoadjuvant treatment with cetrelimab can improve the pathologic complete response (pCR) ...

TAR-200 achieved an 82.4% overall complete response rate in BCG-unresponsive, high-risk NMIBC patients with CIS, with a 45.9% 12-month complete response rate. The median duration of response was 25.8 ...

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients ...

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive ...